hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 05:30:53 - browse：49

The Dr. Gary B. and Pamela S. Williams Tower in Summa Health System's Akron Campus — Summa Health

General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech into everyday appointments and rewarding staff for keeping patients healthy might sound alluring. But the firm’s bold experiment is facing hurdles even before it has started as the community served by the health system it hopes to buy is pushing back.

The Health Assurance Transformation Corp., a General Catalyst entity known as HATCo, unveiled plans last month to acquire Akron safety net provider Summa Health. But since the announcement, residents and local officials have raised questions about who the deal benefits, and who gets left behind.

On Thursday, the Mayor of Akron plans to press HATCo’s chief executive, Marc Harrison, who previously led Intermountain Health, on whether his plan is a profit play or a longer-term investment in the community. At the forefront are citizens’ concerns that the deal will drive up costs, eliminate jobs, reduce the quality of care or even shutter one of just two major hospital systems in the area, about a fifth of whose patients are on Medicaid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Baby aspirin cuts fat buildup in liver disease patients, in small study

Childbirth

Neuroscience’s long legacy of racism

Insmed lung disease drug hits target in key Phase 3 trial

Virtual Event: March of the Biosimilars

knowledge

hotspot

explore

Moonlake's readout produced a cash windfall. Risks remain

AstraZeneca to buy developer of next

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Startling documents reveal new facets of Sacklers' opioid empire

ChatGPT in medicine: STAT answers readers' burning questions

Health AI adoption puts security, privacy startups on investors' radar

In Memoriam: Notable people who died in 2023

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Medicare proposal to cover medical devices draws a mixed reaction

Biohaven protein

explore

Virtual Event: March of the Biosimilars

U.K. researchers warn about biases in medical devices, algorithms

David Sabatini, ex

Neuroscience’s long legacy of racism

Do more moles mean more problems? Not so, says new study

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

focus

knowledge

focus

hotspot